The biotechnology group MorphoSys has placed convertible bonds with a volume of 325 million euros.
The company intends to use the proceeds for acquisitions, in-licensing and general corporate purposes, such as MorphoSys announced on Tuesday in Planegg. The group had announced the placement in the morning. The share then came under significant pressure, but was able to contain the losses somewhat and was still a good 4 percent in the late afternoon.
Video: Share in focus: Gerresheimer counts on the fourth quarter – investors take profits
The Notes with a maturity in 2025 can be converted into new and / or existing no-par value bearer shares of MorphoSys. The subscription right of the company’s existing shareholders to subscribe for the convertible bonds was excluded.
The dilution of the shares by the announced convertible bonds weighed on the MorphoSys share on Tuesday. The paper finally sagged in XETRA trading by 5.35 percent to 97.30 euros. PLANEGG (dpa-AFX)